SCHEMBL4605841

SCHEMBL4605841

CN(C)C(=O)c1cc(NC(=O)Oc2ccccc2)cc(C(=O)N(C)C)c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.61
ALDH1A1 P00352 8/20 0.58
MAPT P10636 5/20 0.58
KMT2A Q03164 4/20 0.58
MEN1 O00255 3/20 0.58
KDM4E B2RXH2 3/20 0.58
THRB P10828 2/20 0.58
GFER P55789 1/20 0.58
TDP1 Q9NUW8 1/20 0.58
BCHE P06276 1/20 0.55
ACHE P22303 1/20 0.55
GAA P10253 3/20 0.51
HTT P42858 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
LMNA P02545 1/20 0.50
TP53 P04637 1/20 0.50
RAD51 Q06609 1/20 0.50
POLB P06746 1/20 0.49
HPGD P15428 2/20 0.48
RAB9A P51151 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5338427 0.89 CYP1A2 (0.74) CYP1A2ALDH1A1MAPTKMT2AMEN1
SCHEMBL24756040 0.85 CYP1A2 (0.54) CYP1A2ALDH1A1MAPTKMT2AMEN1
SCHEMBL2808736 0.83 CYP1A2 (0.65) CYP1A2ALDH1A1MAPTKMT2AMEN1
SCHEMBL2813391 0.82 CYP1A2 (0.64) CYP1A2ALDH1A1MAPTKMT2AMEN1
SCHEMBL2810182 0.81 CYP1A2 (0.63) CYP1A2ALDH1A1MAPTKMT2AMEN1
SCHEMBL2813628 0.80 CYP1A2 (0.65) CYP1A2ALDH1A1MAPTKMT2AMEN1
SCHEMBL2811947 0.79 CYP1A2 (0.64) CYP1A2ALDH1A1MAPTKMT2AMEN1
SCHEMBL2814707 0.77 MAPT (0.62) CYP1A2ALDH1A1MAPTKMT2AMEN1
SCHEMBL24756494 0.77 ALDH1A1 (0.56) CYP1A2ALDH1A1MAPTKMT2AMEN1
SCHEMBL3984703 0.76 ALDH1A1 (0.63) CYP1A2ALDH1A1MAPTKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080306067-A1 Modulators of Chemokine Receptor Activity WEIGAND KLAUS 2008-12-11 US disclosed
EP-1943235-A1 ARYLUREA DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY Novartis AG (CH) 2008-07-16 EP disclosed
WO-2007048771-A1 ARYLUREA DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY NOVARTIS AG (CH) 2007-05-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306067-A1 Modulators of Chemokine Receptor Activity CCR3, CCR1, CCR4 CYP1A2 1758/4885ALDH1A1 906/4885MAPT 4557/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.